Belfast, UK. 7th January, 2019. CV6 Therapeutics Inc., a drug development company focussed on the development and commercialisation of novel combination therapeutics for cancer and inflammatory diseases, today announced that it will be featured as a presenting company at Biotech Showcase™ 2019, to be held on the 7th-9th January at the Hilton San Francisco Union Square. […]

Belfast, UK. 25 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, today announced they would be presenting details on CV6-168, a novel anticancer therapeutic at the 30th EORTC/AACR/NCI Molecular Targets and Cancer Therapeutics Symposium in Dublin, Ireland on 16th of November 2018. The abstract […]

Belfast, U.K. – 18 September, 2018. CV6 Therapeutics (CV6), a drug development company focused on the development and commercialisation of novel combination therapeutics for cancer, announced today that Dr. Robert Ladner, CEO and Founder, was invited to present the Company’s ground-breaking research that led to the development of the novel dUTPase inhibitor and clinical drug […]

Belfast, UK. 17 May, 2018. Robert Ladner, CEO and Founder of CV6 Therapeutics Ltd (CV6), paid tribute today to Professor Patrick G. Johnston at a memorial symposium hosted by Queen’s University Belfast to honour and celebrate the life and accomplishments of “A Leader and Innovator in Cancer Research and Treatment”. Patrick, or ‘Paddy’ to those who […]

Belfast, U.K. – May 17, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of two new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, UK. […]

Belfast, U.K. – March 19, 2018.  CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors. “We are pleased to welcome Richard as our Board Chairman, his extensive experience […]

Belfast, U.K. – April 19, 2018. CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Chris Riviera to the Board of Directors. “We are pleased to welcome Chris to our Board. Chris brings extensive experience in the pharmaceutical […]

With support from Invest Northern Ireland, California based CV6 Therapeutics Ltd has chosen to partner with the Centre for Cancer Research and Cell Biology at Queen’s University, Belfast for a highly innovative R&D project.